Works matching IS 0344-5704 AND VI 64 AND IP 4 AND DT 2009

Results: 27

Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine.

Published in:

2009

By:

Noble CO;
Guo Z;
Hayes ME;
Marks JD;
Park JW;
Benz CC;
Kirpotin DB;
Drummond DC;
Noble, Charles O;
Guo, Zexiong;
Hayes, Mark E;
Marks, James D;
Park, John W;
Benz, Christopher C;
Kirpotin, Dmitri B;
Drummond, Daryl C

Publication type:

journal article

Indomethacin overcomes doxorubicin resistance by decreasing intracellular content of glutathione and its conjugates with decreasing expression of gamma-glutamylcysteine synthetase via promoter activity in doxorubicin-resistant leukemia cells.

Published in:

2009

By:

Asano T;
Tsutsuda-Asano A;
Fukunaga Y;
Asano, Takeshi;
Tsutsuda-Asano, Arisa;
Fukunaga, Yoshitaka

Publication type:

journal article

Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer.

Published in:

2009

By:

Lee GW;
Kim HJ;
Ju JH;
Kim SH;
Kim HG;
Kim TH;
Jeong CY;
Kang JH

Publication type:

Journal Article

Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 857, doi. 10.1007/s00280-009-1062-1

By:

Cornejo, Agustin;
Bohnenblust, Mary;
Harris, Catherine;
Abrahamian, Gregory A.

Publication type:

Article

MTT assays can underestimate cell numbers.

Published in:

2009

By:

Liu, Wai M.;
Dalgleish, Angus G.

Publication type:

Letter

Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 741, doi. 10.1007/s00280-008-0923-3

By:

Noble, Charles O.;
Zexiong Guo;
Hayes, Mark E.;
Marks, James D.;
Park, John W.;
Benz, Christopher C.;
Kirpotin, Dmitri B.;
Drummond, Daryl C.

Publication type:

Article

Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 811, doi. 10.1007/s00280-009-0932-x

By:

Sardão, Vilma A.;
Oliveira, Paulo J.;
Holy, Jon;
Oliveira, Catarina R.;
Wallace, Kendall B.

Publication type:

Article

Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 837, doi. 10.1007/s00280-009-0934-8

By:

Attia, Sabry M.;
Al-Anteet, Alaa A.;
Al-Rasheed, Nouf M.;
Alhaider, Abdulqader A.;
Al-harbi, Mohammed M.

Publication type:

Article

Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 673, doi. 10.1007/s00280-008-0915-3

By:

Nolè, Franco;
Crivellari, D.;
Mattioli, R.;
Pinotti, G.;
Foa, P.;
Verri, E.;
Fougeray, R.;
Brandely, M.;
Goldhirsch, A.

Publication type:

Article

Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 803, doi. 10.1007/s00280-009-0931-y

By:

Pavlick, Anna C.;
Wu, Jennifer;
Roberts, John;
Rosenthal, Mark A.;
Hamilton, Anne;
Wadler, Scott;
Farrell, Kathleen;
Carr, Michelle;
Fry, David;
Murgo, Anthony J.;
Oratz, Ruth;
Hochster, Howard;
Liebes, Leonard;
Muggia, Franco

Publication type:

Article

Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 733, doi. 10.1007/s00280-008-0922-4

By:

Hingorani, Pooja;
Wendong Zhang;
Piperdi, Sajida;
Pressman, Leyna;
Lin, Juan;
Gorlick, Richard;
Kolb, E. Anders

Publication type:

Article

A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 763, doi. 10.1007/s00280-009-0925-9

By:

Ruff, Paul;
Vorobiof, D. A.;
Jordaan, J. P.;
Demetriou, G. S.;
Moodley, S. D.;
Nosworthy, A. L.;
Werner, I. D.;
Raats, J.;
Burgess, L. J.

Publication type:

Article

Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 829, doi. 10.1007/s00280-009-0933-9

By:

Morgan, Lee Roy;
Struck, Robert F.;
Waud, William R.;
LeBlanc, Blaise;
Rodgers, Andrew H.;
Jursic, Branko S.

Publication type:

Article

Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 847, doi. 10.1007/s00280-009-1017-6

By:

Liu, Johnson J.;
Jamieson, Stephen M. F.;
Subramaniam, Joshuan;
Ip, Virginia;
Jong, Nancy N.;
Mercer, Julian F. B.;
McKeage, Mark J.

Publication type:

Article

Indomethacin overcomes doxorubicin resistance by decreasing intracellular content of glutathione and its conjugates with decreasing expression of γ-glutamylcysteine synthetase via promoter activity in doxorubicin-resistant leukemia cells.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 715, doi. 10.1007/s00280-008-0920-6

By:

Asano, Takeshi;
Tsutsuda-Asano, Arisa;
Fukunaga, Yoshitaka

Publication type:

Article

A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 785, doi. 10.1007/s00280-009-0928-6

By:

Bozionelou, Vasiliki;
Kalbakis, Kostas;
Vamvakas, Lambros;
Agelaki, Sofia;
Androulakis, Nikolaos;
Kalykaki, Antonia;
Georgoulias, Vassilis;
Mavroudis, Dimitris

Publication type:

Article

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 777, doi. 10.1007/s00280-009-0927-7

By:

Ramanathan, Ramesh K.;
Belani, Chandra P.;
Singh, Deepti A.;
Tanaka, Michael;
Lenz, Heinz-Josef;
Yun Yen;
Kindler, Hedy L.;
Iqbal, Syma;
Longmate, Jeff;
Mack, Philip C.;
Lurje, Georg;
Gandour-Edwards, Regina;
Dancey, Janet;
Gandara, David R.

Publication type:

Article

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 769, doi. 10.1007/s00280-009-0926-8

By:

Brandes, Alba A.;
Tosoni, A.;
Franceschi, E.;
Blatt, V.;
Santoro, A.;
Faedi, M.;
Amistà, P.;
Gardiman, M.;
Labianca, R.;
Bianchini, C.;
Ermani, M.;
Reni, M.

Publication type:

Article

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 723, doi. 10.1007/s00280-008-0921-5

By:

Conroy, Andrew;
Stockett, David E.;
Walker, Duncan;
Arkin, Michelle R.;
Hoch, Ute;
Fox, Judith A.;
Hawtin, Rachael Elizabeth

Publication type:

Article

Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 657, doi. 10.1007/s00280-008-0913-5

By:

Jeeyun Lee;
Kyung Hae Jung;
Young Suk Park;
Joong Bae Ahn;
Sang Jun Shin;
Seock-Ah Im;
Do Youn Oh;
Dong Bok Shin;
Tae Won Kim;
Namsu Lee;
Jae Ho Byun;
Yong Sang Hong;
Joon Oh Park;
Se Hoon Park;
Ho YeongLim;
Won Ki Kang

Publication type:

Article

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 691, doi. 10.1007/s00280-008-0917-1

By:

Haznedar, Joshua Ö.;
Patyna, Shem;
Bello, Carlo L.;
Peng, Geoffrey W.;
Speed, William;
Xiaoming Yu;
Qingling Zhang;
Sukbuntherng, Juthamas;
Sweeny, David J.;
Antonian, Lida;
Wu, Ellen Y.

Publication type:

Article

Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 665, doi. 10.1007/s00280-008-0914-4

By:

Saunders, Mark P.;
Wilson, Richard;
Peeters, Marc;
Smith, Robert;
Godwood, Alex;
Oliver, Stuart;
Van Cutsem, Eric

Publication type:

Article

Pro-apoptotic and cytostatic activity of naturally occurring cardenolides.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 793, doi. 10.1007/s00280-009-0929-5

By:

Bloise, Elena;
Braca, Alessandra;
De Tommasi, Nunziatina;
Belisario, Maria Antonietta

Publication type:

Article

The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 681, doi. 10.1007/s00280-008-0916-2

By:

Beyer, Carl F.;
Nan Zhang;
Hernandez, Richard;
Vitale, Danielle;
Thai Nguyen;
Ayral-Kaloustian, Semiramis;
Gibbons, James J.

Publication type:

Article

Molecular hydrogen alleviates nephrotoxicity induced by an anti-cancer drug cisplatin without compromising anti-tumor activity in mice.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 753, doi. 10.1007/s00280-008-0924-2

By:

Nakashima-Kamimura, Naomi;
Mori, Takashi;
Ohsawa, Ikuroh;
Asoh, Sadamitsu;
Ohta, Shigeo

Publication type:

Article

Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 707, doi. 10.1007/s00280-008-0918-0

By:

Gyeong-Won Lee;
Hye Junh Kim;
Ji-Hyun Ju;
Seok-Hyun Kim;
Hoon Gu Kim;
Tae Hyo Kim;
Hyun Jin Kim;
Chi-Young Jeong;
Jung Hun Kang

Publication type:

Article

Temozolomide in malignant gliomas: current use and future targets.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 64, n. 4, p. 647, doi. 10.1007/s00280-009-1050-5

By:

Villano, J. Lee;
Seery, Tara E.;
Bressler, Linda R.

Publication type:

Article